EMEA-002944-PIP01-20

Table of contents

Key facts

Active substance
2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid tris(hydroxymethyl)aminomethane salt (1:1) (PF-06882961)
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0452/2021
PIP number
EMEA-002944-PIP01-20
Pharmaceutical form(s)
  • Age-appropriate oral formulation
  • Tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Europe MA EEIG

E-mail: pip_enquiries@pfizer.com
Tel: +44 1304616161

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating